Re-employment of developmental transcription factors in adult heart disease

Seminars in Cell and Developmental Biology

Volumn 18, Issue 1, 2007, Pages 117-131

  Oka, Toru ^a   Xu, Jian ^a   Molkentin, Jeffery D ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Cardiac hypertrophy; Cardiomyopathy; Chromatin; Gene expression; Signaling; Transcription factors

Indexed keywords

ACYLTRANSFERASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; HAND PROTEIN; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYOCYTE ENHANCER FACTOR 2; PROTEIN; SERUM RESPONSE FACTOR; SMAD PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NKX2.5; UNCLASSIFIED DRUG;

CELL DIFFERENTIATION; CELL SPECIFICITY; CHROMATIN; CONGESTIVE CARDIOMYOPATHY; GENE EXPRESSION; GENE FUNCTION; GENETIC CONSERVATION; HEART DEVELOPMENT; HEART DISEASE; HEART MUSCLE CELL; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; NONHUMAN; REVIEW;

EID: 33847261472     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2006.11.012     Document Type: Review

References (222)

1. Akazawa H., and Komuro I. Roles of cardiac transcription factors in cardiac hypertrophy. Circ Res 92 (2003) 1079-1088
2. Klein L., O'Connor C.M., Gattis W.A., Zampino M., de Luca L., Vitarelli A., et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am J Cardiol 91 (2003) 18F-40F
3. Lips D.J., de Windt L.J., van Kraaij D.J., and Doevendans P.A. Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy. Eur Heart J 24 (2003) 883-896
4. Berenji K., Drazner M.H., Rothermel B.A., and Hill J.A. Does load-induced ventricular hypertrophy progress to systolic heart failure?. Am J Physiol Heart Circ Physiol 289 (2005) H8-H16
5. Haider A.W., Larson M.G., Benjamin E.J., and Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 32 (1998) 1454-1459
6. Molkentin J.D., and Dorn II I.G. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 63 (2001) 391-426
7. Force T., Michael A., Kilter H., and Haq S. Stretch-activated pathways and left ventricular remodeling. J Cardiac Fail 8 (2002) S351-S358
8. Selvetella G., Hirsch E., Notte A., Tarone G., and Lembo G. Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence. Cardiovasc Res 63 (2004) 373-380
9. Backs J., and Olson E.N. Control of cardiac growth by histone acetylation/deacetylation. Circ Res 98 (2006) 15-24
10. Molkentin J.D. The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem 275 (2000) 38949-38952
11. Pikkarainen S., Tokola H., Kerkela R., and Ruskoaho H. GATA transcription factors in the developing and adult heart. Cardiovasc Res 63 (2004) 196-207
12. Molkentin J.D., Lin Q., Duncan S.A., and Olson E.N. Requirement of the transcription factor GATA4 for heart tube formation and ventral morphogenesis. Genes Dev 11 (1997) 1061-1072
13. Kuo C.T., Morrisey E.E., Anandappa R., Sigrist K., Lu M.M., Parmacek M.S., et al. GATA4 transcription factor is required for ventral morphogenesis and heart tube formation. Genes Dev 11 (1997) 1048-1060
14. Watt A.J., Battle M.A., Li J., and Duncan S.A. GATA4 is essential for formation of the proepicardium and regulates cardiogenesis. Proc Natl Acad Sci USA 101 (2004) 12573-12578
15. Pu W.T., Ishiwata T., Juraszek A.L., Ma Q., and Izumo S. GATA4 is a dosage-sensitive regulator of cardiac morphogenesis. Dev Biol 275 (2004) 235-244
16. Oka T., Maillet M., Watt A.J., Schwartz R.J., Aronow B.J., Duncan S.A., et al. Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy, compensation, and myocyte viability. Circ Res 98 (2006) 837-845
17. Garg V., Kathiriya I.S., Barnes R., Schluterman M.K., King I.N., Butler C.A., et al. GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature 424 (2003) 443-447
18. Charron F., Paradis P., Bronchain O., Nemer G., and Nemer M. Cooperative interaction between GATA-4 and GATA-6 regulates myocardial gene expression. Mol Cell Biol 19 (1999) 4355-4365
19. Hasegawa K., Lee S.J., Jobe S.M., Markham B.E., and Kitsis R.N. cis-Acting sequences that mediate induction of beta-myosin heavy chain gene expression during left ventricular hypertrophy due to aortic constriction. Circulation 96 (1997) 3943-3953
20. Herzig T.C., Jobe S.M., Aoki H., Molkentin J.D., Cowley Jr. A.W., Izumo S., et al. Angiotensin II type1a receptor gene expression in the heart: AP-1 and GATA-4 participate in the response to pressure overload. Proc Natl Acad Sci USA 94 (1997) 7543-7548
21. Morimoto T., Hasegawa K., Kaburagi S., Kakita T., Wada H., Yanazume T., et al. Phosphorylation of GATA-4 is involved in alpha 1-adrenergic agonist-responsive transcription of the endothelin-1 gene in cardiac myocytes. J Biol Chem 275 (2000) 13721-13726
22. Liang Q., de Windt L.J., Witt S.A., Kimball T.R., Markham B.E., and Molkentin J.D. The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J Biol Chem 276 (2001) 30245-30253
23. Charron F., Tsimiklis G., Arcand M., Robitaille L., Liang Q., Molkentin J.D., et al. Tissue-specific GATA factors are transcriptional effectors of the small GTPase RhoA. Genes Dev 15 (2001) 2702-2719
24. Aries A., Paradis P., Lefebvre C., Schwartz R.J., and Nemer M. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci USA 101 (2004) 6975-6980
25. Hautala N., Tokola H., Luodonpaa M., Puhakka J., Romppanen H., Vuolteenaho O., et al. Pressure overload increases GATA4 binding activity via endothelin-1. Circulation 103 (2001) 730-735
26. Liang Q., Wiese R.J., Bueno O.F., Dai Y.S., Markham B.E., and Molkentin J.D. The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes. Mol Cell Biol 21 (2001) 7460-7469
27. Morisco C., Seta K., Hardt S.E., Lee Y., Vatner S.F., and Sadoshima J. Glycogen synthase kinase 3beta regulates GATA4 in cardiac myocytes. J Biol Chem 276 (2001) 28586-28597
28. Kitta K., Clement S.A., Remeika J., Blumberg J.B., and Suzuki Y.J. Endothelin-1 induces phosphorylation of GATA-4 transcription factor in the HL-1 atrial-muscle cell line. Biochem J 359 (2001) 375-380
29. Kerkela R., Pikkarainen S., Majalahti-Palviainen T., Tokola H., and Ruskoaho H. Distinct roles of mitogen-activated protein kinase pathways in GATA-4 transcription factor-mediated regulation of B-type natriuretic peptide gene. J Biol Chem 277 (2002) 13752-13760
30. Wilkins B.J., and Molkentin J.D. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun 322 (2004) 1178-1191
31. Hogan P.G., Chen L., Nardone J., and Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 17 (2003) 2205-2232
32. Schulz R.A., and Yutzey K.E. Calcineurin signaling and NFAT activation in cardiovascular and skeletal muscle development. Dev Biol 266 (2004) 1-16
33. de la Pompa J.L., Timmerman L.A., Takimoto H., Yoshida H., Elia A.J., Samper E., et al. Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum. Nature 392 (1998) 182-186
34. Ranger A.M., Grusby M.J., Hodge M.R., Gravallese E.M., de la Brousse F.C., Hoey T., et al. The transcription factor NF-ATc is essential for cardiac valve formation. Nature 392 (1998) 186-190
35. Chang C.P., Neilson J.R., Bayle J.H., Gestwicki J.E., Kuo A., Stankunas K., et al. A field of myocardial-endocardial NFAT signaling underlies heart valve morphogenesis. Cell 118 (2004) 649-663
36. Graef I.A., Chen F., Chen L., Kuo A., and Crabtree G.R. Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell 105 (2001) 863-875
37. Bushdid P.B., Osinska H., Waclaw R.R., Molkentin J.D., and Yutzey K.E. NFATc3 and NFATc4 are required for cardiac development and mitochondrial function. Circ Res 92 (2003) 1305-1313
38. Schubert W., Yang X.Y., Yang T.T., Factor S.M., Lisanti M.P., Molkentin J.D., et al. Requirement of transcription factor NFAT in developing atrial myocardium. J Cell Biol 161 (2003) 861-874
39. Molkentin J.D., Lu J.R., Antos C.L., Markham B., Richardson J., Robbins J., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93 (1998) 215-228
40. Wilkins B.J., Dai Y.S., Bueno O.F., Parsons S.A., Xu J., Plank D.M., et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94 (2004) 110-118
41. Wilkins B.J., de Windt L.J., Bueno O.F., Braz J.C., Glascock B.J., Kimball T.F., et al. Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol Cell Biol 22 (2002) 7603-7613
42. van Rooij E., Doevendans P.A., de Theije C.C., Babiker F.A., Molkentin J.D., and de Windt L.J. Requirement of nuclear factor of activated T-cells in calcineurin-mediated cardiomyocyte hypertrophy. J Biol Chem 277 (2002) 48617-48626
43. Kuriyama M., Matsushita M., Tateishi A., Moriwaki A., Tomizawa K., Ishino K., et al. A cell-permeable NFAT inhibitor peptide prevents pressure-overload cardiac hypertrophy. Chem Biol Drug Des 67 (2006) 238-243
44. Haq S., Choukroun G., Kang Z.B., Ranu H., Matsui T., Rosenzweig A., et al. Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol 151 (2000) 117-130
45. Sanbe A., Gulick J., Hanks M.C., Liang Q., Osinska H., and Robbins J. Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res 92 (2003) 609-616
46. Antos C.L., McKinsey T.A., Frey N., Kutschke W., McAnally J., Shelton J.M., et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 99 (2002) 907-912
47. Beals C.R., Sheridan C.M., Turck C.W., Gardner P., and Crabtree G.R. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 275 (1997) 1930-1934
48. Braz J.C., Bueno O.F., Liang Q., Wilkins B.J., Dai Y.S., Parsons S., et al. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J Clin Invest 111 (2003) 1475-1486
49. Liang Q., Bueno O.F., Wilkins B.J., Kuan C.Y., Xia Y., and Molkentin J.D. c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling. Embo J 22 (2003) 5079-5089
50. Baeuerle P.A., and Baltimore D. NF-kappa B: ten years after. Cell 87 (1996) 13-20
51. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J Biol Chem 274 (1999) 27339-27342
52. Haudek S.B., Spencer E., Bryant D.D., White D.J., Maass D., Horton J.W., et al. Overexpression of cardiac I-kappaBalpha prevents endotoxin-induced myocardial dysfunction. Am J Physiol Heart Circ Physiol 280 (2001) H962-H968
53. Carlson D.L., White D.J., Maass D.L., Nguyen R.C., Giroir B., and Horton J.W. I kappa B overexpression in cardiomyocytes prevents NF-kappa B translocation and provides cardioprotection in trauma. Am J Physiol Heart Circ Physiol 284 (2003) H804-H814
54. Kawamura N., Kubota T., Kawano S., Monden Y., Feldman A.M., Tsutsui H., et al. Blockade of NF-kappaB improves cardiac function and survival without affecting inflammation in TNF-alpha-induced cardiomyopathy. Cardiovasc Res 66 (2005) 520-529
55. Jones W.K., Brown M., Wilhide M., He S., and Ren X. NF-kappaB in cardiovascular disease: diverse and specific effects of a "general" transcription factor?. Cardiovasc Toxicol 5 (2005) 183-202
56. Gupta S., Purcell N.H., Lin A., and Sen S. Activation of nuclear factor-kappaB is necessary for myotrophin-induced cardiac hypertrophy. J Cell Biol 159 (2002) 1019-1028
57. Higuchi Y., Otsu K., Nishida K., Hirotani S., Nakayama H., Yamaguchi O., et al. Involvement of reactive oxygen species-mediated NF-kappa B activation in TNF-alpha-induced cardiomyocyte hypertrophy. J Mol Cell Cardiol 34 (2002) 233-240
58. Hirotani S., Otsu K., Nishida K., Higuchi Y., Morita T., Nakayama H., et al. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 105 (2002) 509-515
59. Purcell N.H., Tang G., Yu C., Mercurio F., DiDonato J.A., and Lin A. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci USA 98 (2001) 6668-6673
60. Kawano S., Kubota T., Monden Y., Kawamura N., Tsutsui H., Takeshita A., et al. Blockade of NF-kappaB ameliorates myocardial hypertrophy in response to chronic infusion of angiotensin II. Cardiovasc Res 67 (2005) 689-698
61. Freund C., Schmidt-Ullrich R., Baurand A., Dunger S., Schneider W., Loser P., et al. Requirement of nuclear factor-kappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation 111 (2005) 2319-2325
62. Li Y., Ha T., Gao X., Kelley J., Williams D.L., Browder I.W., et al. NF-kappaB activation is required for the development of cardiac hypertrophy in vivo. Am J Physiol Heart Circ Physiol 287 (2004) H1712-H1720
63. Gossett L.A., Kelvin D.J., Sternberg E.A., and Olson E.N. A new myocyte-specific enhancer-binding factor that recognizes a conserved element associated with multiple muscle-specific genes. Mol Cell Biol 9 (1989) 5022-5033
64. Black B.L., and Olson E.N. Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu Rev Cell Dev Biol 14 (1998) 167-196
65. Molkentin J.D., and Olson E.N. Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors. Proc Natl Acad Sci USA 93 (1996) 9366-9373
66. Rao S., Karray S., Gackstetter E.R., and Koshland M.E. Myocyte enhancer factor-related B-MEF2 is developmentally expressed in B cells and regulates the immunoglobulin J chain promoter. J Biol Chem 273 (1998) 26123-26129
67. Han J., Jiang Y., Li Z., Kravchenko V.V., and Ulevitch R.J. Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 386 (1997) 296-299
68. Skerjanc I.S., and Wilton S. Myocyte enhancer factor 2C upregulates MASH-1 expression and induces neurogenesis in P19 cells. FEBS Lett 472 (2000) 53-56
69. Lin Q., Schwarz J., Bucana C., and Olson E.N. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 276 (1997) 1404-1407
70. Shore P., and Sharrocks A.D. The MADS-box family of transcription factors. Eur J Biochem 229 (1995) 1-13
71. Bi W., Drake C.J., and Schwarz J.J. The transcription factor MEF2C-null mouse exhibits complex vascular malformations and reduced cardiac expression of angiopoietin 1 and VEGF. Dev Biol 211 (1999) 255-267
72. Naya F.J., Black B.L., Wu H., Bassel-Duby R., Richardson J.A., Hill J.A., et al. Mitochondrial deficiency and cardiac sudden death in mice lacking the MEF2A transcription factor. Nat Med 8 (2002) 1303-1309
73. Kolodziejczyk S.M., Wang L., Balazsi K., DeRepentigny Y., Kothary R., and Megeney L.A. MEF2 is upregulated during cardiac hypertrophy and is required for normal post-natal growth of the myocardium. Curr Biol 9 (1999) 1203-1206
74. Molkentin J.D., and Markham B.E. Myocyte-specific enhancer-binding factor (MEF-2) regulates alpha-cardiac myosin heavy chain gene expression in vitro and in vivo. J Biol Chem 268 (1993) 19512-19520
75. Nadruz Jr. W., Kobarg C.B., Constancio S.S., Corat P.D., and Franchini K.G. Load-induced transcriptional activation of c-jun in rat myocardium: regulation by myocyte enhancer factor 2. Circ Res 92 (2003) 243-251
76. Shyu K.G., Ko W.H., Yang W.S., Wang B.W., and Kuan P. Insulin-like growth factor-1 mediates stretch-induced upregulation of myostatin expression in neonatal rat cardiomyocytes. Cardiovasc Res 68 (2005) 405-414
77. Nadruz Jr. W., Corat M.A., Marin T.M., Guimaraes Pereira G.A., and Franchini K.G. Focal adhesion kinase mediates MEF2 and c-Jun activation by stretch: role in the activation of the cardiac hypertrophic genetic program. Cardiovasc Res 68 (2005) 87-97
78. Xu J., Gong N.L., Bodi I., Aronow B.J., Backx P.H., and Molkentin J.D. Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy in transgenic mice. J Biol Chem 281 (2006) 9152-9162
79. Lu J., McKinsey T.A., Nicol R.L., and Olson E.N. Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc Natl Acad Sci USA 97 (2000) 4070-4075
80. Miska E.A., Karlsson C., Langley E., Nielsen S.J., Pines J., and Kouzarides T. HDAC4 deacetylase associates with and represses the MEF2 transcription factor. Embo J 18 (1999) 5099-5107
81. Sparrow D.B., Miska E.A., Langley E., Reynaud-Deonauth S., Kotecha S., Towers N., et al. MEF-2 function is modified by a novel co-repressor, MITR. Embo J 18 (1999) 5085-5098
82. Wang A.H., Bertos N.R., Vezmar M., Pelletier N., Crosato M., Heng H.H., et al. HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor. Mol Cell Biol 19 (1999) 7816-7827
83. Chang S., McKinsey T.A., Zhang C.L., Richardson J.A., Hill J.A., and Olson E.N. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 24 (2004) 8467-8476
84. Zhang C.L., McKinsey T.A., Chang S., Antos C.L., Hill J.A., and Olson E.N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110 (2002) 479-488
85. McKinsey T.A., Zhang C.L., Lu J., and Olson E.N. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature 408 (2000) 106-111
86. McKinsey T.A., Zhang C.L., and Olson E.N. Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc Natl Acad Sci USA 97 (2000) 14400-14405
87. McKinsey T.A., Zhang C.L., and Olson E.N. Identification of a signal-responsive nuclear export sequence in class II histone deacetylases. Mol Cell Biol 21 (2001) 6312-6321
88. Passier R., Zeng H., Frey N., Naya F.J., Nicol R.L., McKinsey T.A., et al. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest 105 (2000) 1395-1406
89. Zhang R., Khoo M.S., Wu Y., Yang Y., Grueter C.E., Ni G., et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med 11 (2005) 409-417
90. Zhang T., Maier L.S., Dalton N.D., Miyamoto S., Ross Jr. J., Bers D.M., et al. The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res 92 (2003) 912-919
91. Naya F.J., Wu C., Richardson J.A., Overbeek P., and Olson E.N. Transcriptional activity of MEF2 during mouse embryogenesis monitored with a MEF2-dependent transgene. Development 126 (1999) 2045-2052
92. Karasseva N., Tsika G., Ji J., Zhang A., Mao X., and Tsika R. Transcription enhancer factor 1 binds multiple muscle MEF2 and A/T-rich elements during fast-to-slow skeletal muscle fiber type transitions. Mol Cell Biol 23 (2003) 5143-5164
93. Kariya K., Farrance I.K., and Simpson P.C. Transcriptional enhancer factor-1 in cardiac myocytes interacts with an alpha 1-adrenergic- and beta-protein kinase C-inducible element in the rat beta-myosin heavy chain promoter. J Biol Chem 268 (1993) 26658-26662
94. Karns L.R., Kariya K., and Simpson P.C. M-CAT, CArG, and Sp1 elements are required for alpha 1-adrenergic induction of the skeletal alpha-actin promoter during cardiac myocyte hypertrophy. Transcriptional enhancer factor-1 and protein kinase C as conserved transducers of the fetal program in cardiac growth. J Biol Chem 270 (1995) 410-417
95. Stewart A.F., Suzow J., Kubota T., Ueyama T., and Chen H.H. Transcription factor RTEF-1 mediates alpha1-adrenergic reactivation of the fetal gene program in cardiac myocytes. Circ Res 83 (1998) 43-49
96. Mao Z., and Wiedmann M. Calcineurin enhances MEF2 DNA binding activity in calcium-dependent survival of cerebellar granule neurons. J Biol Chem 274 (1999) 31102-31107
97. Wu H., Naya F.J., McKinsey T.A., Mercer B., Shelton J.M., Chin E.R., et al. MEF2 responds to multiple calcium-regulated signals in the control of skeletal muscle fiber type. Embo J 19 (2000) 1963-1973
98. Lin J., Wu H., Tarr P.T., Zhang C.Y., Wu Z., Boss O., et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418 (2002) 797-801
99. Handschin C., Rhee J., Lin J., Tarr P.T., and Spiegelman B.M. An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle. Proc Natl Acad Sci USA 100 (2003) 7111-7116
100. Kato Y., Kravchenko V.V., Tapping R.I., Han J., Ulevitch R.J., and Lee J.D. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. Embo J 16 (1997) 7054-7066
101. Marinissen M.J., Chiariello M., Pallante M., and Gutkind J.S. A network of mitogen-activated protein kinases links G protein-coupled receptors to the c-jun promoter: a role for c-Jun NH2-terminal kinase, p38s, and extracellular signal-regulated kinase 5. Mol Cell Biol 19 (1999) 4289-4301
102. Nicol R.L., Frey N., Pearson G., Cobb M., Richardson J., and Olson E.N. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. Embo J 20 (2001) 2757-2767
103. Norman C., Runswick M., Pollock R., and Treisman R. Isolation and properties of cDNA clones encoding SRF, a transcription factor that binds to the c-fos serum response element. Cell 55 (1988) 989-1003
104. Messenguy F., and Dubois E. Role of MADS box proteins and their cofactors in combinatorial control of gene expression and cell development. Gene 316 (2003) 1-21
105. Miano J.M. Serum response factor: toggling between disparate programs of gene expression. J Mol Cell Cardiol 35 (2003) 577-593
106. Belaguli N.S., Schildmeyer L.A., and Schwartz R.J. Organization and myogenic restricted expression of the murine serum response factor gene. A role for autoregulation. J Biol Chem 272 (1997) 18222-18231
107. Croissant J.D., Kim J.H., Eichele G., Goering L., Lough J., Prywes R., et al. Avian serum response factor expression restricted primarily to muscle cell lineages is required for alpha-actin gene transcription. Dev Biol 177 (1996) 250-264
108. Arsenian S., Weinhold B., Oelgeschlager M., Ruther U., and Nordheim A. Serum response factor is essential for mesoderm formation during mouse embryogenesis. Embo J 17 (1998) 6289-6299
109. Niu Z., Yu W., Zhang S.X., Barron M., Belaguli N.S., Schneider M.D., et al. Conditional mutagenesis of the murine serum response factor gene blocks cardiogenesis and the transcription of downstream gene targets. J Biol Chem 280 (2005) 32531-32538
110. Parlakian A., Tuil D., Hamard G., Tavernier G., Hentzen D., Concordet J.P., et al. Targeted inactivation of serum response factor in the developing heart results in myocardial defects and embryonic lethality. Mol Cell Biol 24 (2004) 5281-5289
111. Li S., Czubryt M.P., McAnally J., Bassel-Duby R., Richardson J.A., Wiebel F.F., et al. Requirement for serum response factor for skeletal muscle growth and maturation revealed by tissue-specific gene deletion in mice. Proc Natl Acad Sci USA 102 (2005) 1082-1087
112. Zhang X., Azhar G., Chai J., Sheridan P., Nagano K., Brown T., et al. Cardiomyopathy in transgenic mice with cardiac-specific overexpression of serum response factor. Am J Physiol Heart Circ Physiol 280 (2001) H1782-H1792
113. Zhang X., Chai J., Azhar G., Sheridan P., Borras A.M., Furr M.C., et al. Early postnatal cardiac changes and premature death in transgenic mice overexpressing a mutant form of serum response factor. J Biol Chem 276 (2001) 40033-40040
114. Parlakian A., Charvet C., Escoubet B., Mericskay M., Molkentin J.D., Gary-Bobo G., et al. Temporally controlled onset of dilated cardiomyopathy through disruption of the SRF gene in adult heart. Circulation 112 (2005) 2930-2939
115. Balza Jr. R.O., and Misra R.P. Role of the serum response factor in regulating contractile apparatus gene expression and sarcomeric integrity in cardiomyocytes. J Biol Chem 281 (2006) 6498-6510
116. Davis F.J., Gupta M., Pogwizd S.M., Bacha E., Jeevanandam V., and Gupta M.P. Increased expression of alternatively spliced dominant-negative isoform of SRF in human failing hearts. Am J Physiol Heart Circ Physiol 282 (2002) H1521-H1533
117. Chang J., Wei L., Otani T., Youker K.A., Entman M.L., and Schwartz R.J. Inhibitory cardiac transcription factor, SRF-N, is generated by caspase 3 cleavage in human heart failure and attenuated by ventricular unloading. Circulation 108 (2003) 407-413
118. Sepulveda J.L., Vlahopoulos S., Iyer D., Belaguli N., and Schwartz R.J. Combinatorial expression of GATA4, Nkx2-5, and serum response factor directs early cardiac gene activity. J Biol Chem 277 (2002) 25775-25782
119. Chen C.Y., and Schwartz R.J. Recruitment of the tinman homolog Nkx-2.5 by serum response factor activates cardiac alpha-actin gene transcription. Mol Cell Biol 16 (1996) 6372-6384
120. Sepulveda J.L., Belaguli N., Nigam V., Chen C.Y., Nemer M., and Schwartz R.J. GATA-4 and Nkx-2.5 coactivate Nkx-2 DNA binding targets: role for regulating early cardiac gene expression. Mol Cell Biol 18 (1998) 3405-3415
121. Belaguli N.S., Sepulveda J.L., Nigam V., Charron F., Nemer M., and Schwartz R.J. Cardiac tissue enriched factors serum response factor and GATA-4 are mutual coregulators. Mol Cell Biol 20 (2000) 7550-7558
122. Oh J., Wang Z., Wang D.Z., Lien C.L., Xing W., and Olson E.N. Target gene-specific modulation of myocardin activity by GATA transcription factors. Mol Cell Biol 24 (2004) 8519-8528
123. Callis T.E., Cao D., and Wang D.Z. Bone morphogenetic protein signaling modulates myocardin transactivation of cardiac genes. Circ Res 97 (2005) 992-1000
124. Qiu P., Feng X.H., and Li L. Interaction of Smad3 and SRF-associated complex mediates TGF-beta1 signals to regulate SM22 transcription during myofibroblast differentiation. J Mol Cell Cardiol 35 (2003) 1407-1420
125. Aravind L., and Koonin E.V. SAP-a putative DNA-binding motif involved in chromosomal organization. Trends Biochem Sci 25 (2000) 112-114
126. Wang D., Chang P.S., Wang Z., Sutherland L., Richardson J.A., Small E., et al. Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. Cell 105 (2001) 851-862
127. Wang D.Z., Li S., Hockemeyer D., Sutherland L., Wang Z., Schratt G., et al. Potentiation of serum response factor activity by a family of myocardin-related transcription factors. Proc Natl Acad Sci USA 99 (2002) 14855-14860
128. Xing W., Zhang T.C., Cao D., Wang Z., Antos C.L., Li S., et al. Myocardin induces cardiomyocyte hypertrophy. Circ Res 98 (2006) 1089-1097
129. Chen F., Kook H., Milewski R., Gitler A.D., Lu M.M., Li J., et al. Hop is an unusual homeobox gene that modulates cardiac development. Cell 110 (2002) 713-723
130. Shin C.H., Liu Z.P., Passier R., Zhang C.L., Wang D.Z., Harris T.M., et al. Modulation of cardiac growth and development by HOP, an unusual homeodomain protein. Cell 110 (2002) 725-735
131. Kook H., Lepore J.J., Gitler A.D., Lu M.M., Wing-Man Yung W., Mackay J., et al. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest 112 (2003) 863-871
132. ten Dijke P., and Hill C.S. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 29 (2004) 265-273
133. Derynck R., and Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425 (2003) 577-584
134. Massague J., and Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. Embo J 19 (2000) 1745-1754
135. Delot E.C. Control of endocardial cushion and cardiac valve maturation by BMP signaling pathways. Mol Genet Metab 80 (2003) 27-35
136. Nakajima Y., Yamagishi T., Hokari S., and Nakamura H. Mechanisms involved in valvuloseptal endocardial cushion formation in early cardiogenesis: roles of transforming growth factor (TGF)-beta and bone morphogenetic protein (BMP). Anat Rec 258 (2000) 119-127
137. Schultheiss T.M., Burch J.B., and Lassar A.B. A role for bone morphogenetic proteins in the induction of cardiac myogenesis. Genes Dev 11 (1997) 451-462
138. Monzen K., Hiroi Y., Kudoh S., Akazawa H., Oka T., Takimoto E., et al. Smads, TAK1, and their common target ATF-2 play a critical role in cardiomyocyte differentiation. J Cell Biol 153 (2001) 687-698
139. Galvin K.M., Donovan M.J., Lynch C.A., Meyer R.I., Paul R.J., Lorenz J.N., et al. A role for smad6 in development and homeostasis of the cardiovascular system. Nat Genet 24 (2000) 171-174
140. Brown III C.O., Chi X., Garcia-Gras E., Shirai M., Feng X.H., and Schwartz R.J. The cardiac determination factor, Nkx2-5, is activated by mutual cofactors GATA-4 and Smad1/4 via a novel upstream enhancer. J Biol Chem 279 (2004) 10659-10669
141. Dixon I.M., Hao J., Reid N.L., and Roth J.C. Effect of chronic AT(1) receptor blockade on cardiac Smad overexpression in hereditary cardiomyopathic hamsters. Cardiovasc Res 46 (2000) 286-297
142. Hao J., Wang B., Jones S.C., Jassal D.S., and Dixon I.M. Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro. Am J Physiol Heart Circ Physiol 279 (2000) H3020-H3030
143. Araujo-Jorge T.C., Waghabi M.C., Hasslocher-Moreno A.M., Xavier S.S., Higuchi Mde L., Keramidas M., et al. Implication of transforming growth factor-beta1 in Chagas disease myocardiopathy. J Infect Dis 186 (2002) 1823-1828
144. Hao J., Ju H., Zhao S., Junaid A., Scammell-La Fleur T., and Dixon I.M. Elevation of expression of Smads 2, 3, and 4, decorin and TGF-beta in the chronic phase of myocardial infarct scar healing. J Mol Cell Cardiol 31 (1999) 667-678
145. Cucoranu I., Clempus R., Dikalova A., Phelan P.J., Ariyan S., Dikalov S., et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 97 (2005) 900-907
146. Wang B., Hao J., Jones S.C., Yee M.S., Roth J.C., and Dixon I.M. Decreased Smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart. Am J Physiol Heart Circ Physiol 282 (2002) H1685-H1696
147. Pokharel S., van Geel P.P., Sharma U.C., Cleutjens J.P., Bohnemeier H., Tian X.L., et al. Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin-converting enzyme is related to enhanced breakdown of N-acetyl-Ser-Asp-Lys-Pro and increased phosphorylation of Smad2/3. Circulation 110 (2004) 3129-3135
148. Ikeuchi M., Tsutsui H., Shiomi T., Matsusaka H., Matsushima S., Wen J., et al. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 64 (2004) 526-535
149. Brooks W.W., and Conrad C.H. Myocardial fibrosis in transforming growth factor beta(1)heterozygous mice. J Mol Cell Cardiol 32 (2000) 187-195
150. Wang J., Xu N., Feng X., Hou N., Zhang J., Cheng X., et al. Targeted disruption of Smad4 in cardiomyocytes results in cardiac hypertrophy and heart failure. Circ Res 97 (2005) 821-828
151. Xu J., Kimball T.R., Lorenz J.N., Brown D.A., Bauskin A.R., Klevitsky R., et al. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98 (2006) 342-350
152. Schultz Jel J., Witt S.A., Glascock B.J., Nieman M.L., Reiser P.J., Nix S.L., et al. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 109 (2002) 787-796
153. Rosenkranz S., Flesch M., Amann K., Haeuseler C., Kilter H., Seeland U., et al. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol 283 (2002) H1253-H1262
154. Zhang D., Gaussin V., Taffet G.E., Belaguli N.S., Yamada M., Schwartz R.J., et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 6 (2000) 556-563
155. Komuro I., and Izumo S. Csx: a murine homeobox-containing gene specifically expressed in the developing heart. Proc Natl Acad Sci USA 90 (1993) 8145-8149
156. Lints T.J., Parsons L.M., Hartley L., Lyons I., and Harvey R.P. Nkx-2.5: a novel murine homeobox gene expressed in early heart progenitor cells and their myogenic descendants. Development 119 (1993) 419-431
157. Kasahara H., Bartunkova S., Schinke M., Tanaka M., and Izumo S. Cardiac and extracardiac expression of Csx/Nkx2.5 homeodomain protein. Circ Res 82 (1998) 936-946
158. Stanley E.G., Biben C., Elefanty A., Barnett L., Koentgen F., Robb L., et al. Efficient Cre-mediated deletion in cardiac progenitor cells conferred by a 3′UTR-ires-Cre allele of the homeobox gene Nkx2-5. Int J Dev Biol 46 (2002) 431-439
159. Lyons I., Parsons L.M., Hartley L., Li R., Andrews J.E., Robb L., et al. Myogenic and morphogenetic defects in the heart tubes of murine embryos lacking the homeo box gene Nkx2-5. Genes Dev 9 (1995) 1654-1666
160. Tanaka M., Chen Z., Bartunkova S., Yamasaki N., and Izumo S. The cardiac homeobox gene Csx/Nkx2.5 lies genetically upstream of multiple genes essential for heart development. Development 126 (1999) 1269-1280
161. Biben C., Weber R., Kesteven S., Stanley E., McDonald L., Elliott D.A., et al. Cardiac septal and valvular dysmorphogenesis in mice heterozygous for mutations in the homeobox gene Nkx2-5. Circ Res 87 (2000) 888-895
162. Biben C., and Harvey R.P. Homeodomain factor Nkx2-5 controls left/right asymmetric expression of bHLH gene eHand during murine heart development. Genes Dev 11 (1997) 1357-1369
163. Zou Y., Evans S., Chen J., Kuo H.C., Harvey R.P., and Chien K.R. CARP, a cardiac ankyrin repeat protein, is downstream in the Nkx2-5 homeobox gene pathway. Development 124 (1997) 793-804
164. Bruneau B.G., Bao Z.Z., Tanaka M., Schott J.J., Izumo S., Cepko C.L., et al. Cardiac expression of the ventricle-specific homeobox gene Irx4 is modulated by Nkx2-5 and dHand. Dev Biol 217 (2000) 266-277
165. Pashmforoush M., Lu J.T., Chen H., Amand T.S., Kondo R., Pradervand S., et al. Nkx2-5 pathways and congenital heart disease; loss of ventricular myocyte lineage specification leads to progressive cardiomyopathy and complete heart block. Cell 117 (2004) 373-386
166. Jay P.Y., Harris B.S., Maguire C.T., Buerger A., Wakimoto H., Tanaka M., et al. Nkx2-5 mutation causes anatomic hypoplasia of the cardiac conduction system. J Clin Invest 113 (2004) 1130-1137
167. Schott J.J., Benson D.W., Basson C.T., Pease W., Silberbach G.M., Moak J.P., et al. Congenital heart disease caused by mutations in the transcription factor NKX2-5. Science 281 (1998) 108-111
168. Thompson J.T., Rackley M.S., and O'Brien T.X. Upregulation of the cardiac homeobox gene Nkx2-5 (CSX) in feline right ventricular pressure overload. Am J Physiol 274 (1998) H1569-H1573
169. Saadane N., Alpert L., and Chalifour L.E. Expression of immediate early genes, GATA-4, and Nkx-2.5 in adrenergic-induced cardiac hypertrophy and during regression in adult mice. Br J Pharmacol 127 (1999) 1165-1176
170. Takimoto E., Mizuno T., Terasaki F., Shimoyama M., Honda H., Shiojima I., et al. Up-regulation of natriuretic peptides in the ventricle of Csx/Nkx2-5 transgenic mice. Biochem Biophys Res Commun 270 (2000) 1074-1079
171. Durocher D., Charron F., Warren R., Schwartz R.J., and Nemer M. The cardiac transcription factors Nkx2-5 and GATA-4 are mutual cofactors. Embo J 16 (1997) 5687-5696
172. Lee Y., Shioi T., Kasahara H., Jobe S.M., Wiese R.J., Markham B.E., et al. The cardiac tissue-restricted homeobox protein Csx/Nkx2.5 physically associates with the zinc finger protein GATA4 and cooperatively activates atrial natriuretic factor gene expression. Mol Cell Biol 18 (1998) 3120-3129
173. Shiojima I., Komuro I., Oka T., Hiroi Y., Mizuno T., Takimoto E., et al. Context-dependent transcriptional cooperation mediated by cardiac transcription factors Csx/Nkx-2.5 and GATA-4. J Biol Chem 274 (1999) 8231-8239
174. Song K., Backs J., McAnally J., Qi X., Gerard R.D., Richardson J.A., et al. The transcriptional coactivator CAMTA2 stimulates cardiac growth by opposing class II histone deacetylases. Cell 125 (2006) 453-466
175. Toko H., Zhu W., Takimoto E., Shiojima I., Hiroi Y., Zou Y., et al. Csx/Nkx2-5 is required for homeostasis and survival of cardiac myocytes in the adult heart. J Biol Chem 277 (2002) 24735-24743
176. Kasahara H., Ueyama T., Wakimoto H., Liu M.K., Maguire C.T., Converso K.L., et al. Nkx2.5 homeoprotein regulates expression of gap junction protein connexin 43 and sarcomere organization in postnatal cardiomyocytes. J Mol Cell Cardiol 35 (2003) 243-256
177. Srivastava D. HAND proteins: molecular mediators of cardiac development and congenital heart disease. Trends Cardiovasc Med 9 (1999) 11-18
178. Firulli A.B. A HANDful of questions: the molecular biology of the heart and neural crest derivatives (HAND)-subclass of basic helix-loop-helix transcription factors. Gene 312 (2003) 27-40
179. Firulli A.B., McFadden D.G., Lin Q., Srivastava D., and Olson E.N. Heart and extra-embryonic mesodermal defects in mouse embryos lacking the bHLH transcription factor Hand1. Nat Genet 18 (1998) 266-270
180. Riley P., Anson-Cartwright L., and Cross J.C. The Hand1 bHLH transcription factor is essential for placentation and cardiac morphogenesis. Nat Genet 18 (1998) 271-275
181. Riley P.R., Gertsenstein M., Dawson K., and Cross J.C. Early exclusion of hand1-deficient cells from distinct regions of the left ventricular myocardium in chimeric mouse embryos. Dev Biol 227 (2000) 156-168
182. Srivastava D., Thomas T., Lin Q., Kirby M.L., Brown D., and Olson E.N. Regulation of cardiac mesodermal and neural crest development by the bHLH transcription factor, dHAND. Nat Genet 16 (1997) 154-160
183. Natarajan A., Yamagishi H., Ahmad F., Li D., Roberts R., Matsuoka R., et al. Human eHAND, but not dHAND, is down-regulated in cardiomyopathies. J Mol Cell Cardiol 33 (2001) 1607-1614
184. Thattaliyath B.D., Livi C.B., Steinhelper M.E., Toney G.M., and Firulli A.B. HAND1 and HAND2 are expressed in the adult-rodent heart and are modulated during cardiac hypertrophy. Biochem Biophys Res Commun 297 (2002) 870-875
185. Bar H., Kreuzer J., Cojoc A., and Jahn L. Upregulation of embryonic transcription factors in right ventricular hypertrophy. Basic Res Cardiol 98 (2003) 285-294
186. Milbrandt J. A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor. Science 238 (1987) 797-799
187. Huang R.P., Fan Y., de Belle I., Niemeyer C., Gottardis M.M., Mercola D., et al. Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer 72 (1997) 102-109
188. Levin W.J., Press M.F., Gaynor R.B., Sukhatme V.P., Boone T.C., Reissmann P.T., et al. Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. Oncogene 11 (1995) 1261-1269
189. Eid M.A., Kumar M.V., Iczkowski K.A., Bostwick D.G., and Tindall D.J. Expression of early growth response genes in human prostate cancer. Cancer Res 58 (1998) 2461-2468
190. Swirnoff A.H., and Milbrandt J. DNA-binding specificity of NGFI-A and related zinc finger transcription factors. Mol Cell Biol 15 (1995) 2275-2287
191. Lanoix J., Mullick A., He Y., Bravo R., and Skup D. Wild-type egr1/Krox24 promotes and dominant-negative mutants inhibit, pluripotent differentiation of p19 embryonal carcinoma cells. Oncogene 17 (1998) 2495-2504
192. Saadane N., Alpert L., and Chalifour L.E. Altered molecular response to adrenoreceptor-induced cardiac hypertrophy in Egr-1-deficient mice. Am J Physiol Heart Circ Physiol 278 (2000) H796-H805
193. Buitrago M., Lorenz K., Maass A.H., Oberdorf-Maass S., Keller U., Schmitteckert E.M., et al. The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy. Nat Med 11 (2005) 837-844
194. Montminy M.R., and Bilezikjian L.M. Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. Nature 328 (1987) 175-178
195. Gonzalez G.A., Yamamoto K.K., Fischer W.H., Karr D., Menzel P., Biggs III W., et al. A cluster of phosphorylation sites on the cyclic AMP-regulated nuclear factor CREB predicted by its sequence. Nature 337 (1989) 749-752
196. Habener J.F. Cyclic AMP response element binding proteins: a cornucopia of transcription factors. Mol Endocrinol 4 (1990) 1087-1094
197. Hoeffler J.P., Meyer T.E., Yun Y., Jameson J.L., and Habener J.F. Cyclic AMP-responsive DNA-binding protein: structure based on a cloned placental cDNA. Science 242 (1988) 1430-1433
198. Vallejo M. Transcriptional control of gene expression by cAMP-response element binding proteins. J Neuroendocrinol 6 (1994) 587-596
199. Ginty D.D., Bonni A., and Greenberg M.E. Nerve growth factor activates a Ras-dependent protein kinase that stimulates c-fos transcription via phosphorylation of CREB. Cell 77 (1994) 713-725
200. Barton K., Muthusamy N., Chanyangam M., Fischer C., Clendenin C., and Leiden J.M. Defective thymocyte proliferation and IL-2 production in transgenic mice expressing a dominant-negative form of CREB. Nature 379 (1996) 81-85
201. Kwok R.P., Lundblad J.R., Chrivia J.C., Richards J.P., Bachinger H.P., Brennan R.G., et al. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 370 (1994) 223-226
202. Arias J., Alberts A.S., Brindle P., Claret F.X., Smeal T., Karin M., et al. Activation of cAMP and mitogen responsive genes relies on a common nuclear factor. Nature 370 (1994) 226-229
203. Chrivia J.C., Kwok R.P., Lamb N., Hagiwara M., Montminy M.R., and Goodman R.H. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365 (1993) 855-859
204. Yamamoto K.K., Gonzalez G.A., Biggs III W.H., and Montminy M.R. Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB. Nature 334 (1988) 494-498
205. Sheng M., Thompson M.A., and Greenberg M.E. CREB: a Ca(2+)-regulated transcription factor phosphorylated by calmodulin-dependent kinases. Science 252 (1991) 1427-1430
206. Pilz R.B., and Casteel D.E. Regulation of gene expression by cyclic GMP. Circ Res 93 (2003) 1034-1046
207. Xing J., Ginty D.D., and Greenberg M.E. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 273 (1996) 959-963
208. Goldspink P.H., and Russell B. The cAMP response element binding protein is expressed and phosphorylated in cardiac myocytes. Circ Res 74 (1994) 1042-1049
209. Muller F.U., Boknik P., Horst A., Knapp J., Linck B., Schmitz W., et al. In vivo isoproterenol treatment leads to downregulation of the mRNA encoding the cAMP response element binding protein in the rat heart. Biochem Biophys Res Commun 215 (1995) 1043-1049
210. Muller F.U., Boknik P., Horst A., Knapp J., Linck B., Schmitz W., et al. cAMP response element binding protein is expressed and phosphorylated in the human heart. Circulation 92 (1995) 2041-2043
211. Chen A.E., Ginty D.D., and Fan C.M. Protein kinase A signalling via CREB controls myogenesis induced by Wnt proteins. Nature 433 (2005) 317-322
212. Fentzke R.C., Korcarz C.E., Lang R.M., Lin H., and Leiden J.M. Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart. J Clin Invest 101 (1998) 2415-2426
213. Muller F.U., Lewin G., Baba H.A., Boknik P., Fabritz L., Kirchhefer U., et al. Heart-directed expression of a human cardiac isoform of cAMP-response element modulator in transgenic mice. J Biol Chem 280 (2005) 6906-6914
214. Jenuwein T., and Allis C.D. Translating the histone code. Science 293 (2001) 1074-1080
215. de Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., and van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370 (2003) 737-749
216. Yanazume T., Morimoto T., Wada H., Kawamura T., and Hasegawa K. Biological role of p300 in cardiac myocytes. Mol Cell Biochem 248 (2003) 115-119
217. Vega R.B., Harrison B.C., Meadows E., Roberts C.R., Papst P.J., Olson E.N., et al. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol 24 (2004) 8374-8385
218. Yao T.P., Oh S.P., Fuchs M., Zhou N.D., Ch'ng L.E., Newsome D., et al. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93 (1998) 361-372
219. Yanazume T., Hasegawa K., Morimoto T., Kawamura T., Wada H., Matsumori A., et al. Cardiac p300 is involved in myocyte growth with decompensated heart failure. Mol Cell Biol 23 (2003) 3593-3606
220. Miyamoto S., Kawamura T., Morimoto T., Ono K., Wada H., Kawase Y., et al. Histone acetyltransferase activity of p300 is required for the promotion of left ventricular remodeling after myocardial infarction in adult mice in vivo. Circulation 113 (2006) 679-690
221. Gusterson R.J., Jazrawi E., Adcock I.M., and Latchman D.S. The transcriptional co-activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity. J Biol Chem 278 (2003) 6838-6847
222. Kee H.J., Sohn I.S., Nam K.I., Park J.E., Qian Y.R., Yin Z., et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 113 (2006) 51-59